FDA Approves JANUMET™ For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin In A Single Tablet

 

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET™, the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin (also known as JANUVIA™), and metformin for the treatment of type 2 diabetes. [click link for full article]

Source: FDA Approves JANUMET™ For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin In A Single Tablet